I was in MNTA & took a bath on that one also. If a buy-out was in the works then it makes sense they didn't raise enough cash to fund the current trials. Now that a buy-out didn't occur the market is punishing them with each secondary.
FWIW, after I sold all my sizable RVNC position and investing elsewhere my port has gone up nicely.
The red herring continue to be lack of US partnership and potential dilution to fund commercial launch. And no guarantee FDA would slap 6 mos duration label.
If RVNC doesn’t get that label, no way they can compete against Botox powerhouse esp if they go alone.
News 
Market Data 
Discover 
AI
